Summary
Becton Dickinson and Company (BDX) reported revenues of $4.586 billion for the quarter ended December 30, 2022, a decrease of 2.8% compared to the prior year. This decline was primarily driven by a significant reduction in COVID-19 testing revenue and unfavorable foreign currency translation, which offset underlying volume and pricing improvements in certain segments. The company experienced a net income of $509 million, or $1.70 per diluted share, compared to $677 million ($2.28 per diluted share) in the same period last year. The year-over-year decrease in net income was impacted by the discontinuation of COVID-19 related testing revenue and ongoing inflationary pressures on raw materials, labor, and freight costs. Despite the top-line decline, BD demonstrated resilience with positive volume growth driven by acquisitions and strong demand in its Medical and Interventional segments, particularly in Medication Management Solutions, Pharmaceutical Systems, and Peripheral Intervention. The Life Sciences segment saw a notable decrease in revenue, largely attributable to the drop in COVID-19 testing sales. The company continues to manage costs and navigate macroeconomic challenges, including inflation and supply chain constraints, while also returning capital to shareholders through dividends. Significant ongoing legal matters and regulatory scrutiny, particularly related to the Alaris infusion pump, require continued monitoring.
Financial Highlights
54 data points| Revenue | $4.59B |
| Cost of Revenue | $2.45B |
| Gross Profit | $2.13B |
| R&D Expenses | $313.00M |
| SG&A Expenses | $1.19B |
| Operating Expenses | $4.00B |
| Operating Income | $585.00M |
| Interest Expense | $102.00M |
| Net Income | $509.00M |
| EPS (Basic) | $1.71 |
| EPS (Diluted) | $1.70 |
| Shares Outstanding (Basic) | 283.89M |
| Shares Outstanding (Diluted) | 285.34M |
Key Highlights
- 1Total revenues decreased by 2.8% to $4.586 billion, primarily due to a significant decline in COVID-19 testing revenue and unfavorable foreign currency translation.
- 2Net income decreased to $509 million ($1.70 diluted EPS) from $677 million ($2.28 diluted EPS) in the prior year, impacted by lower COVID-19 testing revenue and rising costs.
- 3Medical segment revenue saw a modest 1.6% increase, driven by Medication Management Solutions and Pharmaceutical Systems, despite a decline in Medication Delivery Solutions.
- 4Life Sciences segment revenue declined by 12.2%, heavily influenced by the reduction in COVID-19 diagnostic testing sales.
- 5Interventional segment revenue grew by 1.3%, supported by strong performance in Surgery and Peripheral Intervention units.
- 6The company paid $281 million in dividends during the quarter, demonstrating a commitment to returning capital to shareholders.
- 7Significant legal and regulatory matters, including product liability claims and the Alaris infusion pump consent decree, continue to be disclosed and require ongoing management attention.